The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.
Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. · 2021
Read The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. by Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7962638.txt.
Introduction
Jang and co-authors present a review of tumour necrosis factor alpha in autoimmune disease and the drugs that block it. The factor was first known for killing tumours. It is now seen as a driver of chronic inflammation when its signalling runs too strong or too long. It binds two receptors and sets off paths that steer cell survival, growth, and change.
Blocking the factor has become a mainstay of care for several autoimmune diseases. Approved blockers show clear power across those conditions. The review explains how the signalling works and where it goes wrong. It then surveys the approved drugs and the new ones in trials. Fresh inhibitors aim at parts of the pathway beyond the factor itself. The authors gather the case for this drug family and its next steps.
Catalog record
| CREATOR | Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics By Dan-in Jang, A-Hyeon Lee, Hye-Yoon Shin, Hyo-Ryeong Song, Jong-Hwi Park, Tae-Bong Kang, Sang-Ryong Lee, Seung-Hoon Yang, Arcangelo Liso, Pio Conti Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms22052719 ABSTRACT Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the necrosis of tumors, but it has been recently identified to have additional important functions as a pathological component of autoimmune diseases. TNF-α binds to two different receptors, which initiate signal transduction pathways. These pathways lead to various cellular responses, including cell survival, differentiation, and proliferation. However, the inappropriate or excessive activation of TNF-α signaling is associated with chronic inflammation and can eventually lead to the development of pathological complications such as autoimmune diseases. Understanding of the TNF-α signaling mechanism has been expanded and applied for the treatment of immune diseases, which has resulted in the development of effective therapeutic tools, including TNF-α inhibitors. Currently, clinically approved TNF-α inhibitors have shown noticeable potency in a variety of autoimmune diseases, and novel TNF-α signaling inhibitors are being clinically evaluated. In this review, we briefly introduce the impact of TNF-α signaling on autoimmune diseases and its inhibitors, which are used as therapeutic agents against autoimmune diseases. 1. INTRODUCTION Tumor necrosis factor alpha (TNF-α) is a cytokine that has pleiotropic effects on various cell types. It has been identified as a major regulator of inflammatory responses and is known to be involved in the pathogenesis of some inflammatory and autoimmune diseases [1]. Structurally, TNF-α is a homotrimer protein consisting of 157 amino acids, mainly generated by activated macrophages, T-lymphocytes, and natural killer cells [2]. It is functionally known to trigger a series of various inflammatory molecules, including other cytokines and chemokines. TNF-α exists in a soluble and transmembrane form. The transmembrane TNF-α (tmTNF-α) is the initially synthesized precursor form and is required to be processed by TNF-α-converting enzyme (TACE), a membrane-bound disintegrin metalloproteinase, to be released as the soluble TNF-α (sTNF-α) [3]. The processed sTNF-α then facilitates various biological activities through type 1 receptors (TNFR1, also known as TNFRSF1A, CD120a, and p55) and type 2 receptors (TNFR2, also known as TNFRSF1B, CD120b, and p75) [4,5,6,7]. tmTNF-α also acts on both TNFR1 and TNFR2, but its biological activities are expected to be mediated mainly through TNFR2 [8]. TNFR1 is expressed by all human tissues and is the key signaling receptor for TNF-α. TNFR2 is generally expressed in immune cells and facilitates limited biological responses [9]. In general, TNF-α binds to its receptors, mainly TNFR1 and TNFR2, and then transmits molecular signals for biological functions such as inflammation and cell death. TNFR1 is activated by both sTNF-α and tmTNF-α, and it processes a death domain (DD) that interacts with the TNFR1-associated death domain (TRADD) adaptor protein [10]. The activation of TNFR1 can trigger the formation of different signaling complexes, referred to as complexes I, IIa, IIb, and IIc, which result in distinct cellular responses [11,12]. During the assembly of complex I, the activated TNFR1 binds to TRADD, followed by the association and interaction of various components, including receptor-interacting serine/threonine-protein kinase 1 (RIPK1), TNFR-associated factor 2 or 5 (TRAF2/5), cellular inhibitor of apoptosis protein 1 or 2 (cIAP1/2), and the linear ubiquitin chain assembly complex (LUBAC) [13]. This signaling pathway results in the activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinases (MAPKs) [14,15]. The functional outcome of complex I signaling is known to be the induction of inflammation, tissue, cell survival and proliferation, and the immune defense against pathogens [12,16]. Unlike complex I, which is assembled at the plasma membrane, complexes IIa, IIb, and IIc are assembled in the cytoplasm [17]. Complex IIa consists of TRADD, RIPK1, TRAF2, cIAP1/2, pro-Caspase-8, and Fas-associated protein with death domain (FADD) [18,19]. Complex IIb has the same composition as complex IIa with the addition of RIPK3 [18]. The formation of complexes IIa and IIb (also known as apoptosome) activates caspase-8 and results in apoptosis. Complex IIc (known as necrosome) is known to be formed by RIPK1 and RIPK3, which bind to form the complex when they remain uncleaved. Complex IIc activates the mixed lineage kinase domain-like protein (MLKL) via RIPK3-mediated phosphorylation, which induces necroptosis and inflammation (Figure 1) [13,20]. TNFR2 is suggested to be fully activated by tmTNF-α, primarily in the context of cell-to-cell interactions. Unlike TNFR1, TNFR2 lacks a death domain and thus is unable to induce programmed cell death directly (Figure 2) [8]. During assembly, TNFR2 recruits TRAF2 along with TRAF1, cIAP1, and cIAP2, and this complex allows the downstream activation of NF-κB, MAPKs, and protein kinase B (AKT) [17]. Functionally, TNFR2 is mainly associated with homeostatic bioactivities, including tissue regeneration, cell proliferation, and cell survival [21]. However, this pathway is also known to trigger inflammatory responses and host defense against pathogens. Overall, TNFR1 is essential to induce cytotoxic and proinflammatory TNF-α responses, while TNFR2 may largely mediate cell activation, migration, or proliferation (Figure 1). Physiologically, TNF-α is a crucial component for a normal immune response. TNF-α can activate the immune system to regulate; however, the inappropriate or excessive production of TNF-α can be harmful and may lead to disease. Rheumatoid arthritis (RA) [22], inflammatory bowel disease (IBD) [23,24,25], psoriatic arthritis (PsA), psoriasis (PS) [26], and noninfectious uveitis (NIU) are induced by the abnormal secretion of TNF-α; thus, TNF-α can be classified as a key factor in the pathological development. Due to the involvement of TNF-α in the pathogenesis of autoimmune diseases, TNF-α inhibitors have been successfully developed and applied in the clinical treatment of autoimmune diseases such as Crohn’s disease (CD) and RA [27,28]. Therapeutic drugs act as antagonists by blocking the interaction of TNF-α with TNFR1/2 or, in some cases, as agonists by stimulating reverse signaling, causing the apoptosis of TNF-α producing immune cells [29,30,31]. Several TNF-α inhibitors have been approved for clinical use: etanercept, infliximab, adalimumab, golimumab, and certolizumab. The impact of TNF-α signaling on each type of autoimmune disease will be introduced in this review, as well as the evaluation of current TNF-α inhibitors utilized as therapeutic drugs against autoimmune diseases. 2. TNF-Α SIGNALING IN AUTOIMMUNE DISEASES 2.1. Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints and typically results in redness, swelling, and arthralgia. In serious cases, it limits the range of motion [32]. RA affects nearly 1% of the population, and it is characterized by the inflammation of synovial tissue, leading to progressive damage, including the erosion of adjacent cartilage and bone, which can lead to chronic disability [33]. TNF-α is considered the major inflammatory cytokine involved in the pathogenesis of RA and is found in high frequencies in patients with the disease. Inflammation is associated with the accumulation of inflammatory cells, predominantly type 1 helper T cells (Th1) and macrophages but also B cells, plasma cells, and dendritic cells (DCs) [22]. In RA, TNF-α secreted from Th1 cells and macrophages activates synovial fibroblasts, promotes epidermal hyperplasia, and recruits inflammatory cells [34]. After activation by various cytokines, including IL-1, IL-6, and TNF-α [35], synovial fibroblasts overexpress cathepsins and matrix metalloproteinases (MMPs), followed by collagen and proteoglycan breakdown. As a result, cartilage and bone